In this study, we performed a pan-cancer analysis of tumor and normal samples from TCGA dataset to evaluate the impacts of ENO1 on prognosis, staging, and immune infiltrating levels in 23 cancer types, including cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), lung adenocarcinoma (LUAD), and kidney chromophobe (KICH). Here, ENO1 is linked to cancer.